

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Greene *et al.*

Appl. No. 09/526,437

Filed: March 15, 2000

For: **Human Tumor Necrosis Factor
Receptor-Like Genes**



Art Unit: 1643

Examiner: To Be Assigned

Atty. Docket: 1488.0710005/EKS/KRM

Information Disclosure Statement

RECEIVED

SEP 25 2000

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AM2 and AN2 are attached.

Copies of the documents AA1, AB1, AC1, AD1, AL1, AM1 AN1, AO1, AP1, AL2, AR1, AS1, AT1, AR2, AS2, AT2, AR3, AS3, AT3, AR4, AS4, AT4, AR5, AS5, AT5, AR6, AS6, AT6, AR7, AS7, AT7, AR8, AS8, AT8, AR9, AS9, AT9, AR10, AS10, AT10, AR11, AS11, AT11, AR12, AS12, AT12, AR13, AS13, AT13, AR14, AS14, AT14, AR15, AS15, AT15, AR16, AS16, AT16, AR17, AS17, AT17, AR18, and AS18 were cited by or submitted to the Office in Application No. 08/469,637, filed June 6, 1995, and U.S. Application No. 08/718,737, filed September 18, 1996 which are relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

The Examiner is also referred to the following list of co-pending patent applications:

U.S. Application No. 08/462,315, filed June 5, 1995;
U.S. Application No. 08/462,962, filed June 5, 1995;
U.S. Application No. 08/464,595, filed June 5, 1995;

U.S. Application No. 08/469,637, filed June 6, 1995;
U.S. Application No. 08/741,095, filed October 30, 1996; and
U.S. Application No. 08/718,737, filed September 18, 1996.

Document AP1, WO 96/26217, is in a foreign language. Document AS18 is an English language translation/equivalent of WO 96/26217.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: 9/21/00

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600